← Back to Clinical Trials
Recruiting NCT05767762

NCT05767762 Evertor Muscle Activity as a Predictor of Achilles Tenotomy in the Management of Idiopathic Varus Equinus Clubfoot

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05767762
Status Recruiting
Phase
Sponsor Fondation Lenval
Condition Clubfoot
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2023-04-26
Primary Completion 2031-03

Eligibility & Interventions

Sex All sexes
Min Age 0 Months
Max Age 12 Months
Study Type INTERVENTIONAL
Interventions
scale Idiopathic Clubfoot

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2023-04-26 with a primary completion date of 2031-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Clubfoot is an orthopedic congenital malformation of the lower limb of the newborn evaluated by the Dimeglio score. There is a deficit of muscular balance between the agonists and antagonists to the deformity. The Dimeglio score takes into account the muscular activity but only up to one point out of 20. This study proposes to use a muscle scale inspired by the Dimeglio score to see if there is a correlation between muscle activity and the risk of tenotomy before 1 year. It will also assess the inter-examiner reproducibility of this scale. This study is a prospective cohort study with a duration of 8 years to include about 100 feet. Infants with idiopathic Clubfoot treated with the functional method at up to 15 days of life will be included. Feet will be assessed at an inclusion visit and then at 3-6-12 months. The primary endpoint will be the need for Achilles tenotomy before 1 year of age. The secondary endpoint will be inter-examiner reproducibility determined by statistical analysis. The expectation of this study would be to define a predictive factor of the evolution of the PBVE in order to refine the treatment earlier.

Eligibility Criteria

Inclusion Criteria: * idiopathic clubfoot, managed by the functional method, managed before D15 to perform the initial assessment. Exclusion Criteria: * syndromic clubfoot, management other than functional method, management after D15

Contact & Investigator

Central Contact

Grégoire Peuchevrier

✉ peuchevrier.g@hpu.lenval.com

📞 492030323

Frequently Asked Questions

Who can join the NCT05767762 clinical trial?

This trial is open to participants of all sexes, aged 0 Months or older, up to 12 Months, studying Clubfoot. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05767762 currently recruiting?

Yes, NCT05767762 is actively recruiting participants. Contact the research team at peuchevrier.g@hpu.lenval.com for enrollment information.

Where is the NCT05767762 trial being conducted?

This trial is being conducted at Nice, France.

Who is sponsoring the NCT05767762 clinical trial?

NCT05767762 is sponsored by Fondation Lenval. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology